triazoles has been researched along with T-Cell Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ | 1 |
| Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, DH | 1 |
1 trial(s) available for triazoles and T-Cell Lymphoma
| Article | Year |
|---|---|
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Etoposide; Humans; Hydrazines; Ifosfamide; Lymphoma, T-Cell; Neoplasm Recurrence, Local; Triazoles | 2021 |
1 other study(ies) available for triazoles and T-Cell Lymphoma
| Article | Year |
|---|---|
Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; Cell Line, Tumor; Chlorides; Crosses, Genetic; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fas Receptor; Female; Ferric Compounds; Gene Expression Regulation, Leukemic; Iron; Iron Chelating Agents; Iron Overload; Iron-Dextran Complex; Leukemia L1210; Liver; Lymphoma, T-Cell; Mice; Mice, Inbred Strains; Neoplasm Proteins; Triazoles; Tumor Burden | 2013 |